Mayne Pharma Group (ASX:MYX) confirmed that it received AU$14.4 million from Cosette Pharmaceuticals in accordance with the Supreme Court of New South Wales' orders, comprising recovery of Mayne's legal costs, costs associated with Mayne's application for costs, and interest, according to a Friday Australian bourse filing.
The company began proceedings against Cosette in June 2025 in relation to Cosette's purported termination of the scheme implementation deed signed by the two parties in February 2025. The court ruled in favor of the company in October 2025 and made an adverse costs order against Cosette.
An appeal against the October 2025 judgment by Cosette was heard in the Supreme Court of New South Wales, Court of Appeal on Tuesday and Wednesday, and a decision was reserved.
Its shares rose over 1% in recent trading on Friday.